GS 6637

Drug Profile

GS 6637

Alternative Names: ANS-6637; GS-6637; GS-6673

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Developer Amygdala Neurosciences
  • Class Drug withdrawal therapies
  • Mechanism of Action Aldehyde dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alcoholism; Drug abuse

Most Recent Events

  • 15 Nov 2017 Amygdala Neurosciences completes a phase I trial in Alcoholism (In volunteers) in USA (PO) (NCT03203499)
  • 27 Jul 2017 Phase-I clinical trials in Alcoholism (In volunteers) in USA (PO) (NCT03203499)
  • 05 Jul 2017 Amygdala Neurosciences plans a phase I trial in Healthy volunteers (NCT03203499)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top